Published in February 2021, this short report examines using the Cambridge Prognostic Groups for risk stratification of prostate cancer in the National Prostate Cancer Audit.
Currently, the risk associated with a man’s prostate cancer is classified as low-, intermediate- or high-risk. A new stratification tool (the Cambridge Prognostic Grouping, CPG) classifies men into five categories based on more detailed information about the clinical features of their disease.
In this short report, we examine the impact of using the new way of stratifying the risk of prostate cancer on the way that potential ‘over-treatment’ is measured in the NPCA.
NPCA Short Report 2021